Clinical Trial Update: A Study of Pasireotide in People With Prolactinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pasireotide for prolactinoma (prolactin-producing pituitary tumor) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prolactinoma

Drugs mentioned

• Pasireotide (Signifor) (pasireotide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prolactin-Producing Pituitary Tumor | Phase 2 | Status: RECRUITING